Governments may onshore part of biopharma supply chain, but it won't be easy: Panel
Singapore
THE Covid-19 pandemic has exposed vulnerabilities in the global biopharmaceutical supply chain, raised renewed concerns over the offshoring of facilities to Asia and highlighted the heavy reliance on large producer markets - such as China and India - for critical medical supplies.
Now, policymakers around the world will thus be compelled to review their supply chain strategy and management so they can ensure supply and mitigate risks.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Luminar to cut nearly 20% jobs as part of restructuring
TD risks an earnings hit from US laundering probe, analysts say
Everything Apple plans to show at May 7 ‘let loose’ iPad event
BNP weighing up to 150 job cuts in Geneva to slash costs
Bitcoin’s wild price swings point to the rising influence of ETF buyers
Paramount will let exclusive talks with Skydance lapse: NYT